FDA Drug Label
WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo, 2021
GLP-1 & MetabolicFDA ApprovedS
Semaglutide
Ozempic / Wegovy / Rybelsus
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- S
- Experience
- 57
- Activity
- 38
Overall check-ins
Trackers & reports
Overview
About Semaglutide
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.
- Category
- GLP-1 & Metabolic
- Regulatory status
- FDA Approved
- Also known as
- Ozempic / Wegovy / Rybelsus
- Self-reports
- 26
Community
What 26 users report
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 96% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
122
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
117
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
32
0.2–0.4 mg
5
0.4–0.6 mg
4
0.6–1 mg
9
1–2 mg
33
2+ mg
39
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 23 repeat reporters
Research
Cited research (3)
Source
FDA Drug Label
OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information
Novo, 2017
PubMed
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding et al., 2021
Tools
Explore more
Explore
More ways to learn about Semaglutide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Semaglutide?
This page summarizes 26 anonymized self-reports from PeptIQ users who track Semaglutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Semaglutide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Semaglutide?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Semaglutide safe to use?
This wiki does not assess safety or recommend use. Semaglutide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Semaglutide?
Research, primarily in animal models, suggests Semaglutide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Semaglutide?
Semaglutide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Semaglutide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Semaglutide?
The safety and effectiveness of Semaglutide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Semaglutide?
While there are over 200 published studies on Semaglutide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source